Health Care · Pharmaceutical Preparations

AVBP ArriVent BioPharma, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 186827949 filings
Russell 2000

AVBP at a glance

ArriVent BioPharma, Inc. (AVBP, SEC CIK 1868279) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding ArriVent BioPharma, Inc. (AVBP) shares worth $384.6 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$384.6M · −1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02 · Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • USPTO ex parte reexamination of RE ’687 Patent, initiated July 2026, could narrow or cancel claims
  • RE ’687 Patent prosecution closed October 19, 2026, with certificate intended to confirm claims
  • Patent validity disputes could eliminate protection for current and future product candidates
  • Patent litigation could divert management and scientific resources and increase defense costs

Management Discussion & Analysis

  • Collaboration revenue $5.0M, versus $0 in Q3 2025, from ARR-002 upfront payment
  • Operating loss $43.4M vs $38.3M YoY, net loss $40.3M vs $35.0M
  • R&D expense $38.9M vs $32.2M, early-stage programs increased $5.1M
  • Cash, equivalents and short-term investments $393.2M; operating cash used $122.2M
  • FURVENT failed its primary endpoint; existing liquidity expected to fund operations through at least twelve months

AI summary of the AVBP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1 press release

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stuart Lutzker, President of R&D and director, retires effective December 1, 2026
  • Departure not related to disagreements, reducing apparent governance or operational conflict risk

Item EX-99.1: Item EX-99.1

  • FURVENT missed its primary PFS endpoint, weakening firmonertinib’s near-term approval case despite 11.0-month PFS vs 9.5 months and ORR 60% vs 33%
  • ALPACCA Phase 3 enrollment remains on track, preserving the lead program’s potential in EGFR PACC-mutant NSCLC
Filed Oct 26, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 1 ARR-217 data showed 44.8% ORR and 93.1% DCR at 6 mg/kg Q3W in pretreated CRC patients
  • Activity extended across doses: 34.2% ORR and 91.8% DCR at 4 mg/kg Q3W and higher

Item 8.01: Other Events

  • Item 8.01 incorporates most of the Item 7.01 press release into the filing
  • Investor significance depends on the underlying press release, which contains the substantive event details

Item 7.01: Regulation FD Disclosure

  • Initial Phase 1 ARR-217 (MRG007) data disclosed in gastrointestinal cancer patients
  • CDH17-targeted antibody-drug conjugate presented at ESMO Congress 2026
Filed Oct 19, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Cancer Cell publication strengthens firmonertinib’s clinical and mechanistic case in underserved EGFR PACC-mutant NSCLC
  • Front-line confirmed ORR reached 43% at 160 mg and 68% at 240 mg, with median PFS of 11.1 and 16.0 months

Item 7.01: Regulation FD Disclosure

  • Publication of Phase 1b FURTHER trial results for firmonertinib in Cancer Cell
  • Results concern FURMO-002, clinical trial NCT05364073

AI summaries of AVBP 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AVBP

Don't miss the next AVBP filing

  • Alerts as it files. A push when AVBP files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AVBP, by share count.
  • Ask anything. An AI agent that reads every AVBP filing and answers with sources.

AVBP alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
LaChapelle RobinMOct 30, 2026-
LaChapelle RobinMOct 30, 2026$3.65
LaChapelle RobinMOct 30, 2026$2.28
LaChapelle RobinMOct 30, 2026$2.28
LaChapelle RobinMOct 30, 2026$2.28
LaChapelle RobinMOct 30, 2026$6.24
LaChapelle RobinMOct 30, 2026-
LaChapelle RobinMOct 30, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$74.6M-$94.3M-$177.5M
Net Income-$69.3M-$80.5M-$166.3M
Balance Sheet
Total Assets$163.1M$274.9M$333.2M
Equity-$153.2M$257.7M$307.2M
ROE45.3%-31.2%-54.1%
Per Share
EPS$-32.38$-2.56$-4.32
Cash Flow
Operating CF-$55.8M-$70.2M-$160.6M

Source: XBRL data in ArriVent BioPharma, Inc. (AVBP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AVBP share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AVBP shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$384.6M
Q2 202626$480.9M
Q1 202624$268.0M
Q4 202523$233.3M
Q3 202521$192.2M
Q2 202518$155.8M
Q1 202515$95.1M
Q4 202411$126.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AVBP filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Nov 2, 2026--
8-KOct 26, 2026Analysis-
8-KOct 19, 2026Analysis-
8-KOct 13, 2026Analysis-
8-KOct 6, 2026Analysis-
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
4Jun 22, 2026--
8-KJun 22, 2026Analysis-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KMay 11, 2026Analysis
10-QMay 11, 2026Analysis
8-KMay 11, 2026Analysis
8-KMar 17, 2026Analysis-
8-KMar 5, 2026Analysis-
10-KMar 5, 2026-
4Feb 4, 2026-
4Feb 4, 2026-
4Feb 4, 2026-
4Feb 4, 2026-
4Feb 4, 2026-

Related Health Care companies

All Health Care →

AVBP SEC filings: frequently asked questions

Which institutions hold AVBP stock?

As of September 30, 2026, the largest ArriVent BioPharma, Inc. (AVBP) holders among the 13F filers tracked by SignalX were BlackRock ($103.2 million), Vanguard Capital Management LLC ($60.9 million), State Street Corp ($53.4 million), Goldman Sachs Group ($33.5 million), Bank of America Corp ($32.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did AVBP report in its latest 8-K?

ArriVent BioPharma, Inc. (AVBP) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest AVBP SEC filings?

ArriVent BioPharma, Inc. (AVBP) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 2, 2026.

What is AVBP's SEC CIK number?

ArriVent BioPharma, Inc. (AVBP)'s SEC Central Index Key (CIK) is 1868279. EDGAR lists every AVBP filing under that number.

Ask anything about AVBP

The research agent reads AVBP's filings, financials, insider trades and 13F holders, then answers with sources.